Biotech Daily

Wednesday September 17, 2025

Daily news on ASX-listed biotechnology companies

*** ASX, BIOTECH DOWN: ALCIDION UP 11%; EMVISION DOWN 12%**

*** EMVISION PLACEMENT RAISES $12m; PLAN FOR $1m MORE**

*** CONTROL BIONICS OFFER, SHORTFALL RAISES $1.5m OF HOPED-FOR $2m**

*** PAINCHEK SCOTLAND REPORT: FEWER SCRIPTS, BETTER LIFE QUALITY**

*** EBR IMPLANTS 10th COMMERCIAL WISE DEVICE**

*** DORSAVI: 'RRAM BEATS BIOLOGICAL REFLEX'**

*** BLINKLAB ADDS MISSOURI UNI TO DX1 AUTISM STUDY**

*** ONCOSIL REQUESTS 'PANCOSIL TRIAL RESULTS' TRADING HALT**

*** CSL 2nd STRIKE VOTE, M-D $12.6m RIGHTS AGM**

*** CRYOSITE 1m M-D ANDREW KERR OPTIONS AGM**

*** TDM REDUCES TO 25% OF SOMNOMED; 16m SHARE 'BLOCK TRADE'**

*** EPSILON: TGA GRANTS SOUTHPORT FACILITY GMP**

*** PYC TO LOSE CEO DR ROHAN HOCKINGS; CHAIR ALAN TRIBE INTERIM**

*** BIO-MELBOURNE 'WOMEN IN LEADERSHIP' AWARDS OPEN**

MARKET REPORT

The Australian stock market fell 0.67 percent on Wednesday September 17, 2025, with the ASX200 down 59.2 points to 8,818.5 points. Fourteen of the Biotech Daily Top 40 companies were up, 20 fell and six traded unchanged.

Alcidion was the best, up one cent or 11.1 percent to 10 cents, with 1.9 million shares traded. Cyclopharm climbed 8.4 percent; 4D Medical, EBR and Medical Developments improved more than seven percent, Clinuvel and Nova Eye were up more than five percent; Botanix and Prescient were up four percent or more; Imricor rose 2.2 percent; Paradigm and SDI were up more than one percent; with Clarity, Neuren and Resmed up by less than one percent.

Emvision led the falls, down 27 cents or 11.6 percent to $2.05, with 332,275 shares traded. Resonance lost 5.6 percent; Avita and Medadvisor fell more than four percent; Compumedics and Micro-X were down more than three percent; Aroa, Cochlear, Cynata, Immutep, Impedimed, Imugene and Pro Medicus shed two percent or more; Genetic Signatures, Mesoblast, Optiscan, Orthocell, Polynovo, Proteomics and Telix fell more than one percent; with CSL, Dimerix and Nanosonics down by less than one percent.

EMVISION MEDICAL DEVICES

Emvision says it has “firm commitments” to raise $12.0 million through an institutional placement at $1.94 a share, with a share plan for up-to $1 million.
Emvision the offer price was a 6.6 percent discount to the 15-day volume weighted average price, and investors would receive three options for every four shares acquired, exercisable at $3.40 each within two years of the issue date
The company said the share plan could accept oversubscriptions, capped at $2 million, had a record date of September 16, would open September 29 and close October 23.
Emvision said the funds would take it to US Food and Drug Administration submission and the initial Emu device commercialization activities and advance the first responder program with trials, production readiness and regulatory preparation.
The company said Barrenjoey and Bell Potter Securities were joint lead managers.
Emvision

CONTROL BIONICS

Control Bionics says its non-renounceable rights issue has raised $309,836, and was underwritten for $1,150,610, for a total of $1.46 million.
In August, Control Bionics said it hoped to raise $2.062 million at 3.5 cents a share in a one-for-five, partially-underwritten, non-renounceable rights offer (BD: Aug 28, 2025).
Today, the company said directors could place the shortfall within the next three months.
Control Bionics

PAINCHEK

Painchek says its pain assessment application led to fewer prescriptions and improvement in quality-of-life indicators in a trial at Scottish aged care facilities.
Painchek said the Scotland Government-funded pilot program, which was independently evaluated by Edinburgh Napier University with the Scottish Care Inspectorate, collected survey data from 50 social care staff and 10 carers, as well as key informant interviews from 12 social care staff and three carers.
The company said the study reported its software led to up to 25 percent less analgesia use, a reduction of laxative and anti-depressant prescriptions by 34 percent and 21 percent, respectively, with quality-of-life improvements including 40 percent fewer falls and less distress, 47 percent increase in body mass index (BMI) scores supporting decreased malnutrition and a 27 percent decrease in medication dependencies.
The report, titled ‘Evaluation of a Digital Solution for the Assessment and Management of Pain in Scottish Care Services’ was conducted by Edinburgh Napier University, Digital Health & Care Innovation Centre and Digital Health & Care Scotland, and was available at: https://bit.ly/4nyHEUS.
Painchek said it estimated about GBP66 million ($A134.8 million) in “cash-releasing benefit” for Scotland Health if its application was implemented in 60 percent of Scottish care homes, covering about 23,000 patients, over five years.
The company said Renaissance Care, its largest client in Scotland, had participated, implemented its application in “all of its services” and had reported “immense benefit”.
Painchek chief executive officer Philip Daffas said two key drivers for government funding for new medical products were “improving patient health and reducing healthcare costs”.
“The Scottish Care Inspectorate pilot [program] has demonstrated that embedding Painchek into the aged-care environment can achieve both,” Mr Daffas said.
Painchek

EBR SYSTEMS

EBR says it has implanted its Wise wireless cardiac pacing device for heart failure in a tenth commercial patient in its US pilot program launch.

EBR said the Phoenix and Scottsdale, Arizona-based Honor Health's Dr Rahul Doshi performed several of the cardiac re-synchronization therapy (CRT) implant procedures, with Honor Health serving a patient population of five million people.

The company said it had approval for the New Technology Add-On Payment targeting inpatients and preliminary approval for Transitional Pass-Through reimbursement, targeting outpatients, with both programs to begin in October 2025.

Dr Rahul Doshi said "the strong clinical evidence from the Solve CRT study was no surprise, as left ventricular endo-cardial pacing is more physiological than the current epi-cardial CRT methods".

"Once reimbursement top-up payments begin, we would look to adopt Wise immediately in patients who failed lead-based CRT and those considered high risk for a conventional upgrade," Dr Doshi said.

EBR chief executive officer John McCutcheon said "passing the 10-case milestone so soon after FDA approval reflects strong clinical interest in leadless left-ventricular endocardial pacing and underscores the value EBR's novel Wise system brings for patients who are not well served by conventional CRT".

"With reimbursement now confirmed for inpatients and preliminary approval received for outpatient settings from October 2025, we are well positioned to expand our footprint and commence our limited market release," Mr McCutcheon said.

EBR

DORSAVI

Dorsavi says its resistive random-access memory (RRAM)-powered Reflex Platform for robotics and biomedical applications has been validated in engineering tasks.

Dorsavi said the tests confirmed its device had the potential to deliver "biological-grade reflexes at unprecedented speed and energy efficiency", with less than or equal to 0.8 microseconds of reflex decision latency, energy cost per reflex decision of between 13 to 127 picojoules, nanojoule-class calibration and adaptation energy and resistive random-access memory (RRAM); meaning that the device was "not memory bound", limiting the shift to external components like sensors, analog to digital converters (ADCs) and actuators.

The company said reflex decisions had to be made within less than or equal to one microsecond in wearable devices and robotic gripping mechanisms, with the analysis confirming its device could execute a complete neural reflex decision on the in-memory RRAM crossbar array in less time, with "ultra-efficient energy consumption".

Dorsavi said robotic systems could use the Reflex Platform to execute "biological-like slip reflexes, instantly tightening grip before object loss", ideal for prevision handling in unpredictable environments, as well as prosthetics, exosuits and human-machine interfaces.

Dorsavi chair Gernot Abl said "we are incredibly proud to share the validation results of our RRAM-enabled Reflex Platform, which confirm its readiness for sub-millisecond, energy-efficient reflex control in real-world applications".

"These outcomes mark a pivotal milestone for Dorsavi as we advance beyond traditional sensor technologies toward neuromorphic systems that can think, adapt, and respond in real time," Mr Abl said.

Dorsavi

BLINKLAB

Blinklab says the Columbia-based University of Missouri's Thompson Center for Autism and Neurodevelopment will join the trial of its Dx1 autism test.
In June, Blinklab said it had ethics approval for the 1,000-patient, main study of its US diagnostic trial of its Dx1 smartphone application for autism (BD: Jun 30, 2025).
Today, Blinklab said it was currently expanding its clinical sites, and that the study would enrol a minimum of 260 children diagnosed with autism and 260 neurotypical children, with enrolment reaching up to a potential 900 children in total, with the study expected to be completed by July 2026.
Blinklab

ONCOSIL MEDICAL

Oncosil has requested a trading halt pending an announcement "in relation to the results of the Pancosil clinical trial".
Trading will resume on September 19, 2025 or on an earlier announcement.
Oncosil

CSL

CSL says its annual general meeting will vote on a potential second remuneration report strike and issue managing-director Dr Paul McKenzie 58,360 performance rights.
CSL said Dr Paul McKenzie's performance rights, part of his long-term incentive and in addition to his $US1,930,883 ($A2,893,409) annual salary, were equivalent to 425 percent of the salary and worth $12,551,625.
Last year, the company said its annual general meeting passed all resolutions but with a 26.4 percent first strike against the remuneration report and 23 percent against managing-director shares (BD: Oct 29, 2024).
Under the Corporations Amendment (Improving Accountability on Director and Executive Remuneration) Act 2011 any company sustaining a vote of 25 percent or more against the remuneration report in two successive annual meetings is required to vote on a board spill.
Today, CSL said shareholders would vote to elect directors Dr Brian Daniels and Cameron Price and adopt its remuneration report.
The meeting will be held at the RACV Club, Level 17, 501 Bourke Street, Melbourne on October 28, 2025 at 10am (AEDT).
CSL

CRYOSITE

Cryosite says its annual general meeting will vote to issue 1.0 million options to managing director Andrew Kerr.
Cryosite said the options would vest in four tranches, and were exercisable at 90 cents, $1.10, $1.20 and $1.30 within five years of issue.
Cryosite said the options were in addition to Mr Kerr's $196,080 salary.
The company said shareholders would vote to approve its remuneration report, adopt its option plan and approve its additional 10 percent placement capacity.
The meeting will be held at 525 Collins Street, Melbourne on October 16, 2025 at 11am (AEDT).
Cryosite

SOMNOMED

The Sydney-based TDM Growth Partners says it has reduced its shareholding in Somnomed from 67,716,079 shares (31.33%) to 54,504,649 shares (24.98%).
TDM Growth Partners said that on September 25, 2023 it sold 13,211,430 shares on market for 70 cents a share.
Separately, Somnomed said a block trade of 16,071,430 shares at 70 cents a share was completed on September 16, 2025, with 2,860,000 shares from the Somnomed employee share trust traded, being "residual issued shares within a legacy structure", and the other 13,211,430 shares from TDM Growth Partners.
The company said TDM Growth Partners had agreed to a "restriction on selling further shares for a period ending after the announcement of interim results in February 2026".
Somnomed

EPSILON HEALTHCARE

Epsilon says the Therapeutics Goods Administration (TGA) has issued its Southport facility on the Gold Coast, Queensland good manufacturing practice certification.
Epsilon said the updated certificate covered its subsidiary Epsilon Pharma's Southport manufacturing facility in Australia, Europe and the UK until June 16, 2026.
Epsilon

PYC THERAPEUTICS

PYC says chief executive officer Dr Rohan Hockings expects to resign on November 16, 2025, with chair Alan Tribe to act as interim chief executive on $80,000 a year.
PYC said Mr Tribe had served the board since 2018 and was well versed in the company's operations.
Mr Tribe thanked Dr Hockings "for his significant contributions to the company and wish him well in the future" and said a search had begun for a new chief executive officer.
PYC

BIO-MELBOURNE NETWORK

The Bio-Melbourne Network says it will open nominations for its 2026 Women in Leadership awards at its Bioforum, from today, September 17, 2025.
The Bio-Melbourne Network said the awards "recognize and champion women, including trans women and gender diverse people, at different stages of their careers who have made outstanding contributions to Australia's health technologies sector, strengthen the sector's diversity and inspire more women to pursue leadership roles".
The Network said the three awards were: Emerging Leadership Award – Mover and Shaker; Inspiring Leadership Award – Catalysing collaboration and powering progress; and Distinguished Leadership Award – Impact for Industry.
To apply, go to: https://bit.ly/46C9DNT.